Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (trading symbol: ARPO) on August 17, 2021. The report details a material definitive agreement entered into on the same date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is a one-time cash payment of $450,000 received from EyePoint Pharmaceuticals, Inc. for the sale of specific assets.
Material Changes and Agreements
On August 17, 2021, Aerpio Pharmaceuticals entered into an Asset Purchase Agreement with EyePoint Pharmaceuticals, Inc. Under this agreement, Aerpio agreed to sell all rights, title, and interest in the following assets:
- The Phase 2 program for razuprotafib in glaucoma.
- The Phase 2 program of razuprotafib in COVID-19.
- Preclinical Tie2 activating antibodies.
In exchange, Aerpio received a one-time cash payment of $450,000. The closing of this agreement is contingent upon and effective only after the closing of the merger between Aerpio Pharmaceuticals and Aadi Bioscience, Inc., which was approved by stockholders on August 17, 2021.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the contingency of the merger closing. The transaction is structured to occur post-merger with Aadi Bioscience, Inc.
Investor Verification Checklist
- Verify the status of the merger between Aerpio Pharmaceuticals and Aadi Bioscience, Inc., as the asset sale is contingent upon its closing.
- Confirm the receipt of the $450,000 cash payment from EyePoint Pharmaceuticals, Inc.
- Review the full text of the Asset Purchase Agreement (Exhibit 10.1) for omitted schedules or additional terms.
- Assess the impact of divesting the razuprotafib and Tie2 antibody programs on the company's future pipeline.